Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid

References

• Briggs GG, Freeman RK, Yaffe SJ. Acitretin. Drugs in Pregnancy and Lactation, 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011.
   Google Scholar
• Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–41.
   PubMed Web of Science ®Google Scholar
• Use of Acitretin/Etitretinate in Pregnancy. UK Teratology Information Service, 2012.
   Google Scholar
• Barbero P, Lotersztein V, Bronberg R, et al. Acitretin embryopathy: a case report. Birth Defects Res Part A Clin Mol Teratol. 2004;70:831–3.
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, de Jong-Van Den Berg LT, van Voorst-Vader PC, et al. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharmacol. 1994;38:229–35.
   PubMed Web of Science ®Google Scholar
• Logistics H. Neotigason Data Sheet. International Core Data Sheet. In: Logistics H, ed. Pharmacy Retailing NZ ltd Healthcare Logistics. New Zealand Medicines and Medical Devices Safety Authority; 2010.
   Google Scholar
• Maier H, Honigsmann H. Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity. Br J Dermatol. 2001;145:1027–8.
   PubMed Web of Science ®Google Scholar
• Rollman O, Pihl-Lundin I. Acitretin excretion into human breast milk. Acta Derm Venereol. 1990;70:487–90.
   PubMed Web of Science ®Google Scholar
• Geiger JM, Walker M. Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane? Dermatology (Basel). 2002;205:105–7.
   PubMed Web of Science ®Google Scholar
• Millsop JW, Heller MM, EM J, MJ E. Dermatological medication effects on male fertility. Dermatologic Therapy. 2013;26:337–46.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ, Tretinoin (Topical). Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011.
   Google Scholar
• Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218–20.
   PubMed Web of Science ®Google Scholar
• Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. The Lancet. 1993;341:1352–3.
   PubMed Web of Science ®Google Scholar
• Panchaud A, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52:1844–51.
   PubMed Web of Science ®Google Scholar
• Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet Part a. 2005;136:117–21.
   PubMedGoogle Scholar
• Martinez-Frias ML, Rodriguez-Pinilla ER. First-trimester exposure to topical tretinoin: its safety is not warranted. Teratology. 1999;60:(1):5.
   Google Scholar
• GSK. Alitretinoin Information Leaflet. In: GSK, ed. England, Wales: GlaxoSmithKline; 2012.
   Google Scholar
• Schmitt-Hoffmann AH, Roos B, Sauer J, et al. Low levels of alitretinoin in seminal fluids after repeated oral doses in healthy men. Clin Exp Dermatol. 2011;36(Supplement 2):12–17.
   PubMedGoogle Scholar
• Ayme S, Julian C, Gambarelli D, et al. Isotretinoin dose and teratogenicity. Lancet. 1988;1:655.
   PubMedGoogle Scholar
• Jahn AF, Ganti K. Major auricular malformations due to Accutane (isotretinoin). Laryngoscope. 1987;97:832–5.
   PubMed Web of Science ®Google Scholar
• Cohen M, Rubenstein A, Jk L, Natheson G. Thymic hypoplasia associated with isotretinoin embryopathy. Am J Dis Child. 1987;141:263–6.
   PubMedGoogle Scholar
• Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol. 1984;10:851–4.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Isotretinoin. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 777–8.
   Google Scholar
• Use of Isotretinoin in Pregnancy [Internet]. UK Teratology Information Service. 2008.
   Google Scholar
• Pharma R. Roaccutane patient product information leaflet. United Kingdom: Roche Pharma AG; 2012.
   Google Scholar
• Hoting VE, Schutte B, Schirren C. Isotretinoin treatment of acne conglobata. Andrological follow up. Fortschr Med. 1992;110(23):427–30.
   PubMedGoogle Scholar
• Padmanabhan S, Tripathi DN, Vikram A, et al. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: Intervention of folic and folinic acid. Mutation Res. 2009;673:43–52.
   PubMed Web of Science ®Google Scholar
• MacDonald K, Norman WV, Popescu O. New anomalies due to methotrexate and misoprostol exposure in early pregnancy. Int J Gynaecol Obstetr. 2013;122:267–8.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Methotrexate. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 928–32.
   Google Scholar
• Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57:51–5.
   PubMedGoogle Scholar
• Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92:551–63.
   PubMed Web of Science ®Google Scholar
• Roman Corona-Riviera J, Rea-Rosas A, Santana-Ramirez A, et al. Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome. Am J Med Genet. 2010;152A:1741–6.
   PubMed Web of Science ®Google Scholar
• Use of Low Dose Methotrexate in Pregnancy. UK Teratology Information Service. 2010.
   Google Scholar
• Pediatrics CoD-AAo. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.
   PubMed Web of Science ®Google Scholar
• Paternal Exposure to Methotrexate [Internet]. UK Teratology Information Service. 2010.
   Google Scholar
• Grunewald S, Paasch U, Glander H-J. Systemic dermatological treatment with relevance for male fertility. J Dtsch Dermatol Ges. 2007;5:15–21.
   PubMedGoogle Scholar
• Use of Mycophenylate Mofetil in Pregnancy [Internet]. UK Teratology Information Service. 2010.
   Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Mycophenolate. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011.
   Google Scholar
• Vento M, Perez Aytes A, Ledo A, et al. Mycophenolate mofetil during pregnancy: some words of caution. Pediatrics. 2008;122:184–5.
   PubMed Web of Science ®Google Scholar
• Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant. 2013;13:1383–9.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European network of teratology information services. Am J Med Genet. 2012;158A(3):588–96.
   PubMed Web of Science ®Google Scholar
• Anderka MT, Lin A, E, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:(Part A):1241–8.
   PubMedGoogle Scholar
• Tjeertes IFA, Bastiaans DET, van Ganzewinkel CJLM, Zegers SHJ. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol. 2007;27:62–4.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013;13:470–5.
   PubMed Web of Science ®Google Scholar
• Roll A, Reich K, Boer A. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol. 2007;73:1337.
   PubMed Web of Science ®Google Scholar
• Photochemotherapy and fumaric acid. In: Schaefer C, Peters P, Miller RK, ed. Drugs During Pregnancy and Lactation Treatment options and risk assessment. 2nd ed. Great Britain: Elsevier; 2007. p. 456.
   Google Scholar
• Fumaric Acid Esters Information Leaflet [Internet]. British Association of Dermatologists. 2010.
   Google Scholar
• Connell WR. Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflamm Bowel Dis. 1996;2:33–47.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Koneru B, Wang C-CP, et al. Cyclosporine and its metabolites in mother and baby. Transplantation. 1988;46:468–9.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Cyclosporine. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 351–3.
   Google Scholar
• Bae Y-SC, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(3):459–77.
   PubMedGoogle Scholar
• Cochat P, Decramer S, Robert-Gnansia E, Dubourg L. Renal outcome of children exposed to cyclosporine in utero. Transplant Proc. 2004;36(Supplement 2S):208S–10S.
   PubMedGoogle Scholar
• Use of Ciclosporin in Pregnancy [Internet]. UK Teratology Information Service. 2011.
   Google Scholar
• Nulman I, Edell H. Paediatric outcomes following in utero exposure to the diagnosis and treatment of maternal malignancy. Eur J Cancer. 2011;47:S217–S29.
   PubMed Web of Science ®Google Scholar
• Morton A. Cyclosporine and lactation. Nephrology (Carlton). 2011;16:249–50.
   PubMed Web of Science ®Google Scholar
• Thiru Y, Bateman DN, Coulthard MG. Successful breast feeding while mother was taking cyclosporin. BMJ. 1997;315:463.
   PubMed Web of Science ®Google Scholar
• Seethalakshmi L, Flores C, Carboni AA, et al. Cyclosporine: its effects on testicular function and fertility in the prepubertal rat. J Androl. 1990;11:17–24.
   PubMed Web of Science ®Google Scholar
• Use of Azathioprine/6-Mercaptopurine in Pregnancy [Internet]. UK Teratology Information Service. 2010.
   Google Scholar
• Hutson JR, Lubetsky A, Walfisch A, et al. The transfer of 6-mercaptopurine in the dually perfused human placenta. Reprod Toxicol. 2011;32:349–53.
   PubMed Web of Science ®Google Scholar
• Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother. 2005;6:1833–9.
   PubMed Web of Science ®Google Scholar
• Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol. 2004;18:219–30.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Azathioprine. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 120–1.
   Google Scholar
• Shim L, Eslick GD, Simring AA, et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5:234–8.
   PubMed Web of Science ®Google Scholar
• Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res Part A Clin Mol Teratol. 2009;85:647–54.
   PubMed Web of Science ®Google Scholar
• Temprano KK, Bandlamudio MD, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum. 2005;35:112–21.
   PubMed Web of Science ®Google Scholar
• Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985;92:233–9.
   PubMedGoogle Scholar
• Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161–74.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Anstey AV, Mohd Mustapa MF, et al. British association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine. Br J Dermatol. 2011;165:711–34.
   PubMed Web of Science ®Google Scholar
• Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160:610–19.
   PubMed Web of Science ®Google Scholar
• Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28:1209–13.
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5:95–100.
   PubMed Web of Science ®Google Scholar
• Sau A, Clarke S, Kaiser A, et al. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114:498–501.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol. 2006;62:453–6.
   PubMed Web of Science ®Google Scholar
• Paternal Use of Azathioprine/6-Mercaptopurine [Internet]. UK Teratology Information Service. 2010.
   Google Scholar
• Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatologic Therapy. 2013;26:354–63.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: A prospective comparative observational study. Reprod Toxicol. 2013;39:58–62.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48:3207–11.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–7.
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69:1827–30.
   PubMed Web of Science ®Google Scholar
• Renault F, Flores-Guevara R, Renaud C, et al. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr. 2009;98(9):1500–3.
   PubMed Web of Science ®Google Scholar
• Climaz R, Brucato A, Meregalli E, et al. LETTERS: electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum. 2004;50:3049–60.
   Google Scholar
• Sperber K, Horn C, Chao CP, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J. 2009;7:9.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Motta M. Therapy Insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol. 2007;3:400–6.
   PubMedGoogle Scholar
• Nicola WG, Khayria MI, Osfor MM. Plasma testosterone level and the male genital system after chloroquine therapy. Boll Chim Farm. 1997;136:39–43.
   PubMedGoogle Scholar
• Use of Chloroquine in Pregnancy [Internet]. UK Teratology Information Service. 2008.
   Google Scholar
• Brabin BJ, Egglete TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. Drug Safety. 2004;27:633–48.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Dapsone. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 366–8.
   Google Scholar
• Tuffanelli DL. Successful pregnancy in a patient with dermatitis herpetiformis treated with low-dose dapsone. Arch Dermatol. 1982;118:876.
   PubMedGoogle Scholar
• Use of Etanercept in Pregnancy [Internet]. UK Teratology Information Service. 2011.
   Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Etancercept. In: Wilkins LWa, ed. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2011. p. 351–3.
   Google Scholar
• Berthlot J-M, Bandt MD, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28–34.
   PubMed Web of Science ®Google Scholar
• Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumour necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol. 2008;36:635–41.
   Web of Science ®Google Scholar
• Murase JE, Heller M, Butler DC. Safety of dermatologic medications in pregnancy and lactation, Part 1 Pregnancy. J Am Acad Dermatol. 2014;70:401 e1–14.
   PubMed Web of Science ®Google Scholar
• Keeling S, Wolbink G-J. Measuring Multiple Etanercept Levels in the Breast Milk of a Nursing Mother with Rheumatoid Arthritis.
   Google Scholar
• Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, et al. Etanercept concentration in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225–7.
   PubMed Web of Science ®Google Scholar
• Borrego L. Etanercep in pregnancy and breast-feeding. Actas Dermosfiliogr. 2010;101(Supplement 1):97–101.
   PubMedGoogle Scholar
• Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation. J Am Acad Dermatol. 2014;70:e1–417. e10.
   PubMedGoogle Scholar
• Use of Infliximab in Pregnancy [Internet]. UK Teratology Information Service. 2009.
   Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Infliximab. Drugs in Pregnancy and Lactation. 9th ed. Lippincott Williams and Wilkins, 2011. p. 744–7.
   Google Scholar
• Marchioni RM, Lichenstein GR. Tumour necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591–602.
   PubMed Web of Science ®Google Scholar
• Shrim A, Koren G. Tumour necrosis factor alpha and use of infliximab – saftey during pregnancy. Can Fam Physician. 2005;51.
   Web of Science ®Google Scholar
• Yiu ZZN, Griffiths CEM, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171(3):485–91.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, de Haar C, de Riddler L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–8.
   PubMed Web of Science ®Google Scholar
• O'Donnell S, O'Morain C. Review article: use of anti-tumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27:885–94.
   PubMed Web of Science ®Google Scholar
• Cheent K, Nolan J, Sohail S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603–5.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555–8.
   PubMed Web of Science ®Google Scholar
• Paschou S, Voulgari PV, Vrabie IG, et al. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol. 2009;36:351–4.
   PubMed Web of Science ®Google Scholar
• Saougou J, Markatseli TE, Papagoras C, et al. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine. 2013;80:34–7.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Adalimumab. Drugs in Pregnancy and Lactation. Lippincott Williams nad Wilkins, 2011. p. 23–5.
   Google Scholar
• Use of Adalimumab in Pregnancy [Internet]. UK Teratology Information Service. Public Health England; 2011.
   Google Scholar
• Jürgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis. 2010;16:1634–6.
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Ustekinumab. Drugs in Pregnancy and Lactation. Lippincott Williams and Wilkins, 2011. p. 1502–3.
   Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the Cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Research Part B: Developmental and Reproductive Toxicology. Wiley-Liss Inc;. 2010;89:351–63.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;4:105–7.
   Google Scholar